Sanofi Secures FDA Approval for Tzield in Type 1 Diabetes Treatment

The Food and Drug Administration has granted accelerated approval to Sanofi’s Tzield, clearing the drug for use in children aged eight to 17 diagnosed with stage 3 type 1 diabetes. The therapy aims to slow the decline of endogenous insulin production for patients facing the early, progressive stages of the autoimmune condition.

Jun 13, 02:21· Money Talk

Approximately 64,000 individuals receive a type 1 diabetes diagnosis annually. Aaron Kowalski, chief executive of Breakthrough T1D, noted that this expansion provides a vital option for patients reaching the stage 3 threshold, a point where clinical symptoms typically begin to manifest.

Sanofi confirmed that the drug has already secured regulatory clearance across several international markets, including the European Union, the United Kingdom, China, Australia, and Canada. Further reviews remain underway in additional jurisdictions as the company seeks to broaden global access to the treatment.

Sanofi Secures FDA Approval for Tzield in Type 1 Diabetes Treatment

Comments (0)